Skip to main content
Top
Published in: Japanese Journal of Ophthalmology 2/2019

01-03-2019 | Vitrectomy | Clinical Investigation

Treatment of macular hemorrhage in retinal arterial microaneurysm: anatomic site-oriented therapy

Authors: Yorihisa Kitagawa, Akiyo Kawamorita, Hiroyuki Shimada, Hiroyuki Nakashizuka

Published in: Japanese Journal of Ophthalmology | Issue 2/2019

Login to get access

Abstract

Purpose

To investigate the usefulness of anatomic site-oriented therapy for macular hemorrhage secondary to retinal arterial macroaneurysm (RAM).

Study design

Retrospective observational study, clinical case series

Methods

Twenty-seven consecutive patients (27 eyes) with macular hemorrhage secondary to RAM were classified according to the retinal layer(s) with hemorrhage identified by optical coherence tomography into 4 types and treated differentially. Vitrectomy was conducted for subinternal limiting membrane hemorrhage (SILMH), intravitreal gas injection for subretinal hemorrhage (SRH) or intraretinal hemorrhage (IRH), and vitrectomy and intravitreal air/gas exchange for multilevel hemorrhage (at least 2 among SILMH/SRH/IRH).

Results

Complete displacement or resolution of the macular hemorrhage was achieved in all 27 eyes: 7 with SILMH, 7 with SRH, 3 with IRH, and 10 with multilevel hemorrhage. Compared with the baseline score, the 3-month postoperative Early Treatment Diabetic Retinopathy Study score (mean ± SD) improved significantly in SILMH (+42.9 ± 6.9 letters; P < .0001, paired t test), multilevel hemorrhage (+23.9 ± 14.4 letters; P = .0005), and SRH (+17.7 ± 18.4 letters; P = .0440), but not in IRH (+6.7 ± 9.0 letters; P = .3228). Compared with the baseline thickness, the 3-month postoperative central retinal thickness decreased significantly in multilevel hemorrhage (-930.3 ± 290.8 µm; P < .0001), SILMH (-628.4 ± 177.0 µm; P < .0001), IRH (-508.3 ± 72.1 µm; P = .0066), and SRH (-476.9 ± 300.0 µm; P = .0056). The central ellipsoid zone was detectable in 7/7 eyes with SILMH but in none of the eyes in the other 3 groups (P < .0001). No retinal detachment or macular hole occurred in any eyes.

Conclusion

For macular hemorrhage secondary to RAM, anatomic site-oriented therapy using different treatments targeting the hemorrhagic retinal layers is useful. The optimal treatments for individual hemorrhagic retinal layers require further studies.
Literature
1.
go back to reference Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. 2010;94:48–53.CrossRefPubMed Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. 2010;94:48–53.CrossRefPubMed
2.
go back to reference Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010;4:67–72.CrossRefPubMedPubMedCentral Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010;4:67–72.CrossRefPubMedPubMedCentral
3.
go back to reference Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96:708–13.CrossRefPubMed Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96:708–13.CrossRefPubMed
4.
go back to reference van Zeeburg EJ, Cereda MG, van Meurs JC. Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2013;251:733–40.CrossRefPubMed van Zeeburg EJ, Cereda MG, van Meurs JC. Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2013;251:733–40.CrossRefPubMed
5.
go back to reference Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta S, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol. 2014;157:1250–7.CrossRefPubMed Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta S, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol. 2014;157:1250–7.CrossRefPubMed
6.
go back to reference Kadonosono K, Arakawa A, Yamane S, Inoue M, Yamakawa T, Uchio E, et al. Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology. 2015;122:123–8.CrossRefPubMed Kadonosono K, Arakawa A, Yamane S, Inoue M, Yamakawa T, Uchio E, et al. Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology. 2015;122:123–8.CrossRefPubMed
7.
go back to reference Kimura S, Morizane Y, Hosokawa M, Shiode Y, Hirano M, Doi S, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. 2015;159:683–9.CrossRefPubMed Kimura S, Morizane Y, Hosokawa M, Shiode Y, Hirano M, Doi S, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. 2015;159:683–9.CrossRefPubMed
8.
go back to reference Inoue M, Shiraga F, Shirakata Y, Morizane Y, Kimura S, Hirakata A. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2015;253:1663–9.CrossRefPubMed Inoue M, Shiraga F, Shirakata Y, Morizane Y, Kimura S, Hirakata A. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2015;253:1663–9.CrossRefPubMed
9.
go back to reference Sonmez K, Ozturk F, Ozcan PY. Treatment of multilevel macular hemorrhage secondary to retinal arterial macroaneurysm with submacular tissue plasminogen activator. Eur J Ophthalmol. 2012;22:1026–31.CrossRefPubMed Sonmez K, Ozturk F, Ozcan PY. Treatment of multilevel macular hemorrhage secondary to retinal arterial macroaneurysm with submacular tissue plasminogen activator. Eur J Ophthalmol. 2012;22:1026–31.CrossRefPubMed
10.
go back to reference Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116:1326–32.CrossRefPubMed Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116:1326–32.CrossRefPubMed
11.
go back to reference Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106:1900–6.CrossRefPubMed Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106:1900–6.CrossRefPubMed
12.
go back to reference Hattenbach LO, Klais C, Koch FH, Gümbel HO. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108:1485–92.CrossRefPubMed Hattenbach LO, Klais C, Koch FH, Gümbel HO. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108:1485–92.CrossRefPubMed
13.
go back to reference Wu TT, Sheu SJ. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage secondary to retinal artery macroaneurysm. J Ocul Pharmacol Ther. 2005;21:62–7.CrossRefPubMed Wu TT, Sheu SJ. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage secondary to retinal artery macroaneurysm. J Ocul Pharmacol Ther. 2005;21:62–7.CrossRefPubMed
14.
go back to reference Sacu S, Stifter E, Vécsei-Marlovits PV, Michels S, Schütze C, Prünte C, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond). 2009;23:1404–10.CrossRefPubMed Sacu S, Stifter E, Vécsei-Marlovits PV, Michels S, Schütze C, Prünte C, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond). 2009;23:1404–10.CrossRefPubMed
15.
go back to reference Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249:1153–7.CrossRefPubMed Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249:1153–7.CrossRefPubMed
16.
go back to reference Guthoff R, Guthoff T, Meigen T, Goebel W. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. 2011;31:36–40.CrossRefPubMed Guthoff R, Guthoff T, Meigen T, Goebel W. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. 2011;31:36–40.CrossRefPubMed
17.
go back to reference Mayer WJ, Hakim I, Haritoglou C, Gandorfer A, Ulbig M, Kampik A, et al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol. 2013;91:274–8.CrossRefPubMed Mayer WJ, Hakim I, Haritoglou C, Gandorfer A, Ulbig M, Kampik A, et al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol. 2013;91:274–8.CrossRefPubMed
18.
go back to reference Shin JY, Lee JM, Byeon SH. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. 2015;159:904–14.CrossRefPubMed Shin JY, Lee JM, Byeon SH. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. 2015;159:904–14.CrossRefPubMed
19.
go back to reference Kitagawa Y, Shimada H, Mori R, Tanaka K, Yuzawa M. Intravitreal tissue plasminogen activator, ranibizumab, and gas injection for submacular hemorrhage in polypoidal choroidal vasculopathy. Ophthalmology. 2016;123:1278–86.CrossRefPubMed Kitagawa Y, Shimada H, Mori R, Tanaka K, Yuzawa M. Intravitreal tissue plasminogen activator, ranibizumab, and gas injection for submacular hemorrhage in polypoidal choroidal vasculopathy. Ophthalmology. 2016;123:1278–86.CrossRefPubMed
20.
go back to reference van Zeeburg EJ, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2013;229:1–14.CrossRefPubMed van Zeeburg EJ, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2013;229:1–14.CrossRefPubMed
21.
go back to reference Kim JH, Chang YS, Lee DW, Kim CG, Kim JW. Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;62:54–62.CrossRefPubMed Kim JH, Chang YS, Lee DW, Kim CG, Kim JW. Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;62:54–62.CrossRefPubMed
22.
go back to reference Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723–9.CrossRefPubMed Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723–9.CrossRefPubMed
23.
go back to reference Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762–73.CrossRefPubMed Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762–73.CrossRefPubMed
24.
go back to reference Benner JD, Hay A, Landers MB 3rd, Hjelmeland LM, Morse LS. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology. 1994;101:672–81.CrossRefPubMed Benner JD, Hay A, Landers MB 3rd, Hjelmeland LM, Morse LS. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology. 1994;101:672–81.CrossRefPubMed
25.
go back to reference Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97–102.CrossRefPubMed Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97–102.CrossRefPubMed
26.
go back to reference Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol. 2013;251:1885–90.CrossRefPubMed Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol. 2013;251:1885–90.CrossRefPubMed
27.
go back to reference Iijima H, Satoh S, Tsukahara S. Nd: YAG laser photodisruption for preretinal hemorrhage due to retinal macroaneurysm. Retina. 1998;18:430–4.CrossRefPubMed Iijima H, Satoh S, Tsukahara S. Nd: YAG laser photodisruption for preretinal hemorrhage due to retinal macroaneurysm. Retina. 1998;18:430–4.CrossRefPubMed
28.
go back to reference Ulbig MW, Mangouritsas G, Rothbacher HH, Hamilton AM, McHugh JD. Long-term results after drainage of premacular subhyaloid hemorrhage into the vitreous with a pulsed Nd: YAG laser. Arch Ophthalmol. 1998;116:1465–9.CrossRefPubMed Ulbig MW, Mangouritsas G, Rothbacher HH, Hamilton AM, McHugh JD. Long-term results after drainage of premacular subhyaloid hemorrhage into the vitreous with a pulsed Nd: YAG laser. Arch Ophthalmol. 1998;116:1465–9.CrossRefPubMed
29.
go back to reference Tashimo A, Mitamura Y, Ohtsuka K, Okushiba U, Imaizumi H, Takeda M. Macular hole formation following ruptured retinal arterial macroaneurysm. Am J Ophthalmol. 2003;135:487–92.CrossRefPubMed Tashimo A, Mitamura Y, Ohtsuka K, Okushiba U, Imaizumi H, Takeda M. Macular hole formation following ruptured retinal arterial macroaneurysm. Am J Ophthalmol. 2003;135:487–92.CrossRefPubMed
30.
go back to reference Sagara N, Kawaji T, Koshiyama Y, Inomata Y, Fukushima M, Tanihara H. Macular hole formation after macular haemorrhage associated with rupture of retinal arterial macroaneurysm. Br J Ophthalmol. 2009;93:1337–40.CrossRefPubMed Sagara N, Kawaji T, Koshiyama Y, Inomata Y, Fukushima M, Tanihara H. Macular hole formation after macular haemorrhage associated with rupture of retinal arterial macroaneurysm. Br J Ophthalmol. 2009;93:1337–40.CrossRefPubMed
31.
go back to reference Pichi F, Morara M, Torrazza C, Manzi G, Alkabes M, Balducci N, et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms. Am J Ophthalmol. 2013;155:287–94.CrossRefPubMed Pichi F, Morara M, Torrazza C, Manzi G, Alkabes M, Balducci N, et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms. Am J Ophthalmol. 2013;155:287–94.CrossRefPubMed
32.
go back to reference Cho HJ, Rhee TK, Kim HS, Han JI, Lee DW, Cho SW, et al. Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm. Am J Ophthalmol. 2013;155:898–904.CrossRefPubMed Cho HJ, Rhee TK, Kim HS, Han JI, Lee DW, Cho SW, et al. Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm. Am J Ophthalmol. 2013;155:898–904.CrossRefPubMed
33.
go back to reference Godel V, Blumenthal M, Regenbogen L. Arterial macroaneurysm of the retina. Ophthalmologica. 1977;175:125–9.CrossRefPubMed Godel V, Blumenthal M, Regenbogen L. Arterial macroaneurysm of the retina. Ophthalmologica. 1977;175:125–9.CrossRefPubMed
Metadata
Title
Treatment of macular hemorrhage in retinal arterial microaneurysm: anatomic site-oriented therapy
Authors
Yorihisa Kitagawa
Akiyo Kawamorita
Hiroyuki Shimada
Hiroyuki Nakashizuka
Publication date
01-03-2019
Publisher
Springer Japan
Keyword
Vitrectomy
Published in
Japanese Journal of Ophthalmology / Issue 2/2019
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-019-00653-y

Other articles of this Issue 2/2019

Japanese Journal of Ophthalmology 2/2019 Go to the issue